Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: cyclosporine

Summary for Generic Name: cyclosporine

Drug Master File Entries: see list15
Suppliers: see list4
Therapeutic Class:Immunological Agents
Ophthalmic Agents

Clinical Trials for: cyclosporine

A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients
Status: Completed Condition: Liver Transplantation

Low Dose Cyclosporin A in Primary Sjögren Syndrome
Status: Active, not recruiting Condition: Sjögren´s Syndrome

Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
Status: Completed Condition: Kidney Transplantation

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
Status: Completed Condition: Psoriasis

Drug Interaction Study of Isavuconazole and Cyclosporine
Status: Completed Condition: Healthy

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye
Status: Completed Condition: Dry Eye Syndromes

Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients
Status: Completed Condition: End Stage Renal Failure

PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects
Status: Active, not recruiting Condition: Healthy

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
Status: Active, not recruiting Condition: Paroxysmal Nocturnal Hemoglobinuria; Hemoglobinuria; Hemoglobinuria, Paroxysmal; Proteinuria; Urination Disorders; Thrombosis; Bone Marrow Failure; Aplastic Anemia,; Anemia, Hemolytic

Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Status: Completed Condition: Atopic Keratoconjunctivitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
CAPSULE;ORAL065040May 9, 2002RXNo<disabled>
Ivax Sub Teva Pharms
CAPSULE;ORAL065110Mar 29, 2005RXNo<disabled>
CAPSULE;ORAL065017Jan 13, 2000RXNo<disabled>
Watson Labs Inc
CAPSULE;ORAL065044Dec 20, 2000RXNo<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology